vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and HUTCHMED (China) Ltd (HCM). Click either name above to swap in a different company.
HUTCHMED (China) Ltd is the larger business by last-quarter revenue ($270.8M vs $247.1M, roughly 1.1× ANI PHARMACEUTICALS INC). ANI PHARMACEUTICALS INC runs the higher net margin — 11.1% vs 0.7%, a 10.4% gap on every dollar of revenue. On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs -16.5%). ANI PHARMACEUTICALS INC produced more free cash flow last quarter ($29.1M vs $3.4M).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
HUTCHMED (China) LtdHCMEarnings & Financial Report
HUTCHMED (China) Ltd is a biopharmaceutical firm focused on discovering, developing and commercializing targeted and immunotherapies for oncology and immunological diseases. It operates across China and global markets, with multiple marketed oncology drugs and a robust pipeline of late-stage clinical candidates addressing unmet patient needs.
ANIP vs HCM — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $270.8M |
| Net Profit | $27.5M | $2.0M |
| Gross Margin | — | 37.7% |
| Operating Margin | 14.1% | -13.2% |
| Net Margin | 11.1% | 0.7% |
| Revenue YoY | 29.6% | -16.5% |
| Net Profit YoY | 367.5% | -83.6% |
| EPS (diluted) | $1.14 | $0.00 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $247.1M | $270.8M | ||
| Q3 25 | $227.8M | — | ||
| Q2 25 | $211.4M | $277.7M | ||
| Q1 25 | $197.1M | $324.5M | ||
| Q4 24 | $190.6M | — | ||
| Q3 24 | $148.3M | — | ||
| Q2 24 | $138.0M | $305.7M | ||
| Q1 24 | $137.4M | — |
| Q4 25 | $27.5M | $2.0M | ||
| Q3 25 | $26.6M | — | ||
| Q2 25 | $8.5M | $455.0M | ||
| Q1 25 | $15.7M | $11.9M | ||
| Q4 24 | $-10.3M | — | ||
| Q3 24 | $-24.2M | — | ||
| Q2 24 | $-2.3M | $25.8M | ||
| Q1 24 | $18.2M | — |
| Q4 25 | — | 37.7% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.1% | ||
| Q1 25 | — | 48.0% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 41.1% | ||
| Q1 24 | — | — |
| Q4 25 | 14.1% | -13.2% | ||
| Q3 25 | 15.9% | — | ||
| Q2 25 | 6.6% | -1.3% | ||
| Q1 25 | 13.3% | -5.0% | ||
| Q4 24 | -2.3% | — | ||
| Q3 24 | -13.8% | — | ||
| Q2 24 | 3.7% | -9.0% | ||
| Q1 24 | 14.8% | — |
| Q4 25 | 11.1% | 0.7% | ||
| Q3 25 | 11.7% | — | ||
| Q2 25 | 4.0% | 163.8% | ||
| Q1 25 | 8.0% | 3.7% | ||
| Q4 24 | -5.4% | — | ||
| Q3 24 | -16.3% | — | ||
| Q2 24 | -1.7% | 8.4% | ||
| Q1 24 | 13.2% | — |
| Q4 25 | $1.14 | $0.00 | ||
| Q3 25 | $1.13 | — | ||
| Q2 25 | $0.36 | $0.52 | ||
| Q1 25 | $0.69 | $0.01 | ||
| Q4 24 | $-0.45 | — | ||
| Q3 24 | $-1.27 | — | ||
| Q2 24 | $-0.14 | $0.03 | ||
| Q1 24 | $0.82 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $1.4B |
| Total DebtLower is stronger | — | $93.2M |
| Stockholders' EquityBook value | $540.7M | $1.2B |
| Total Assets | $1.4B | $1.8B |
| Debt / EquityLower = less leverage | — | 0.08× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $285.6M | $1.4B | ||
| Q3 25 | $262.6M | — | ||
| Q2 25 | $217.8M | $1.4B | ||
| Q1 25 | $149.8M | $836.1M | ||
| Q4 24 | $144.9M | — | ||
| Q3 24 | $145.0M | — | ||
| Q2 24 | $240.1M | $802.5M | ||
| Q1 24 | $228.6M | — |
| Q4 25 | — | $93.2M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $93.4M | ||
| Q1 25 | — | $82.8M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $82.1M | ||
| Q1 24 | — | — |
| Q4 25 | $540.7M | $1.2B | ||
| Q3 25 | $505.8M | — | ||
| Q2 25 | $436.8M | $1.2B | ||
| Q1 25 | $418.6M | $759.9M | ||
| Q4 24 | $403.7M | — | ||
| Q3 24 | $405.9M | — | ||
| Q2 24 | $455.8M | $740.1M | ||
| Q1 24 | $452.0M | — |
| Q4 25 | $1.4B | $1.8B | ||
| Q3 25 | $1.4B | — | ||
| Q2 25 | $1.3B | $1.8B | ||
| Q1 25 | $1.3B | $1.3B | ||
| Q4 24 | $1.3B | — | ||
| Q3 24 | $1.3B | — | ||
| Q2 24 | $920.8M | $1.3B | ||
| Q1 24 | $914.5M | — |
| Q4 25 | — | 0.08× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.08× | ||
| Q1 25 | — | 0.11× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.11× | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $8.2M |
| Free Cash FlowOCF − Capex | $29.1M | $3.4M |
| FCF MarginFCF / Revenue | 11.8% | 1.2% |
| Capex IntensityCapex / Revenue | 0.5% | 1.8% |
| Cash ConversionOCF / Net Profit | 1.10× | 4.21× |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | $-96.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.4M | $8.2M | ||
| Q3 25 | $44.1M | — | ||
| Q2 25 | $75.8M | $-72.9M | ||
| Q1 25 | $35.0M | $40.3M | ||
| Q4 24 | $15.9M | — | ||
| Q3 24 | $12.5M | — | ||
| Q2 24 | $17.4M | $-39.8M | ||
| Q1 24 | $18.3M | — |
| Q4 25 | $29.1M | $3.4M | ||
| Q3 25 | $38.0M | — | ||
| Q2 25 | $71.8M | $-82.2M | ||
| Q1 25 | $32.5M | $32.5M | ||
| Q4 24 | $13.5M | — | ||
| Q3 24 | $7.7M | — | ||
| Q2 24 | $13.0M | $-49.9M | ||
| Q1 24 | $13.7M | — |
| Q4 25 | 11.8% | 1.2% | ||
| Q3 25 | 16.7% | — | ||
| Q2 25 | 34.0% | -29.6% | ||
| Q1 25 | 16.5% | 10.0% | ||
| Q4 24 | 7.1% | — | ||
| Q3 24 | 5.2% | — | ||
| Q2 24 | 9.4% | -16.3% | ||
| Q1 24 | 10.0% | — |
| Q4 25 | 0.5% | 1.8% | ||
| Q3 25 | 2.7% | — | ||
| Q2 25 | 1.9% | 3.3% | ||
| Q1 25 | 1.3% | 2.4% | ||
| Q4 24 | 1.3% | — | ||
| Q3 24 | 3.2% | — | ||
| Q2 24 | 3.2% | 3.3% | ||
| Q1 24 | 3.3% | — |
| Q4 25 | 1.10× | 4.21× | ||
| Q3 25 | 1.66× | — | ||
| Q2 25 | 8.87× | -0.16× | ||
| Q1 25 | 2.23× | 3.38× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -1.54× | ||
| Q1 24 | 1.00× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
HCM
Segment breakdown not available.
